Altre lingue Veru Inc.

Azioni

VERU

US92536C1036

Tempo reale stimato Cboe BZX Altri mercati azionari 17:50:55 08/05/2024			Variaz. 5gg	Var. 1 gen.
1,545 ^USD	-5,21%		+3,02%	+113,19%

06/05	VERU INC. : giudizio positivo da HC Wainwright	ZM
30/04	Veru Inc. arruola i primi pazienti nello studio clinico di Fase 2b della combinazione di Enobosarm e Semaglutide per una perdita di peso di alta qualità	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	14:34
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program	12:30
Veru to Present at the GLP-1 Based Therapeutics Summit	02/05
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024	01/05
Veru : Corporate Presentation, May 2024	30/04
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	30/04
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11	25/04
Veru Announces Date of 2024 Annual Meeting of Shareholders	01/04
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	01/04
Veru Reschedules Annual Meeting of Shareholders	25/03
Veru Reschedules Annual Meeting of Shareholders	22/03
Certain Options of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03
Certain Common Stock of Veru Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	13/03
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss	12/03
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	12/03
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q	28/02
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN	21/02
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss	20/02
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	20/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Veru Inc.

Azioni

VERU

US92536C1036

Altre lingue

Filtri